Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference

Détails

ID Serval
serval:BIB_E055B6E85E1A
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference
Périodique
Kidney Int
Auteur⸱e⸱s
Goodship T. H., Cook H. T., Fakhouri F., Fervenza F. C., Fremeaux-Bacchi V., Kavanagh D., Nester C. M., Noris M., Pickering M. C., Rodriguez de Cordoba S., Roumenina L. T., Sethi S., Smith R. J.
Collaborateur⸱rice⸱s
Conference, Participants
ISSN
1523-1755 (Electronic)
ISSN-L
0085-2538
Statut éditorial
Publié
Date de publication
03/2017
Volume
91
Numéro
3
Pages
539-551
Langue
anglais
Notes
Goodship, Timothy H J
Cook, H Terence
Fakhouri, Fadi
Fervenza, Fernando C
Fremeaux-Bacchi, Veronique
Kavanagh, David
Nester, Carla M
Noris, Marina
Pickering, Matthew C
Rodriguez de Cordoba, Santiago
Roumenina, Lubka T
Sethi, Sanjeev
Smith, Richard J H
eng
G1002528/MRC_/Medical Research Council/United Kingdom
Congress
Kidney Int. 2017 Mar;91(3):539-551. doi: 10.1016/j.kint.2016.10.005. Epub 2016 Dec 16.
Résumé
In both atypical hemolytic uremic syndrome (aHUS) and C3 glomerulopathy (C3G) complement plays a primary role in disease pathogenesis. Herein we report the outcome of a 2015 Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference where key issues in the management of these 2 diseases were considered by a global panel of experts. Areas addressed included renal pathology, clinical phenotype and assessment, genetic drivers of disease, acquired drivers of disease, and treatment strategies. In order to help guide clinicians who are caring for such patients, recommendations for best treatment strategies were discussed at length, providing the evidence base underpinning current treatment options. Knowledge gaps were identified and a prioritized research agenda was proposed to resolve outstanding controversial issues.
Mots-clé
Animals, Atypical Hemolytic Uremic Syndrome/drug therapy/genetics/*immunology/pathology, *Complement Activation/drug effects, Complement C3/genetics/*immunology, Complement Inactivating Agents/therapeutic use, Genetic Predisposition to Disease, Glomerulonephritis/drug therapy/genetics/*immunology/pathology, Humans, Kidney/drug effects/*immunology/pathology, Phenotype, Risk Factors, Treatment Outcome, *C3 glomerulopathy, *anti-complement therapies, *atypical hemolytic uremic syndrome, *complement, *glomerulonephritis, *kidney disease
Pubmed
Création de la notice
01/03/2022 10:18
Dernière modification de la notice
02/03/2022 6:36
Données d'usage